Physician profile
John Jacob
NPI 1386176691
$3,806.86
in general payments reported to CMS, 2019-2025
26 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.63 · 2022: $914 · 2023: $990 · 2024: $798 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,854.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,845.76 | 2022-2025 | |
| Lilly USA, LLC | $281.45 | 2022-2025 | Mounjaro |
| Ardelyx, INC. | $266.99 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $162.78 | 2021-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $154.60 | 2023-2025 | Veozah |
| Amgen INC. | $139.99 | 2022-2023 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals Lp | $120.36 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $116.34 | 2023 | |
| Inspire Medical Systems, INC. | $110.16 | 2023-2025 | Inspire |
| Dexcom, INC. | $108.55 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.05 | 2023-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company Ltd. | $61.16 | 2022 | |
| Mannkind Corporation | $59.40 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.43 | 2025 | |
| Exact Sciences Corporation | $50.22 | 2023-2024 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.19 | 2022-2023 | Jardiance |
| Abiomed | $24.58 | 2025 | |
| Daiichi Sankyo INC. | $18.40 | 2023 | Injectafer |
| Lundbeck LLC | $18.04 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $15.97 | 2022 | |
| Abbott Laboratories | $15.90 | 2025 | Freestyle Libre 3 |
| Itamar Medical INC | $15.62 | 2024 | Watchpatone |
| Janssen Pharmaceuticals, INC | $14.44 | 2021 | |
| Axsome Therapeutics, INC. | $14.08 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $12.07 | 2022 | |
| Dynavax Technologies Corporation | $9.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.